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1. Introduction 
Despite over a century of studies on schizophrenia, its pathogenesis still remains 
unexplained. In particular, cognitive dysfunctions, related to a decrease of prefrontal cortex 
activity in the human brain represent one of the main symptoms of schizophrenia. The 
cognitive dysfunctions usually precede, by a few years, the first acute episode of the disease. 
These dysfunctions are present in approximately 70% of persons suffering from 
schizophrenia, and can be maintained at a stable level over the rest of their lifetime (Rund et 
al., 2006). For instance, majority of patients enrolled in the CATIE study suffered from the 
cognitive disorders (Lieberman et al., 2005a).  
According to Javitt (2010), the cognitive deficits are the key symptoms of schizophrenia, 
which usually precede an onset of some other symptoms of this disease. Due to that, the 
cognitive disorders can represent the leading concept among hypotheses, related to etiology 
of schizophrenia. The main component of these disorders is the deterioration of attention 
concentration and operative memory deficits, including the difficulty of holding some 
elements in short-term memory (Goldman-Rakic, 1999) that in turn translates into some 
cognitive dysfunctions. These disorders include also memory, learning abilities, and 
executive functions (Meltzer & McGurk, 2004). The cognitive dysfunctions related to 
hypofrontality consist of deterioration of the activity of prefrontal brain cortex (Carter et al., 
1998). 
In majority of patients, the cognitive deficits begin prior to their first disease episode, in the 
prodromal stage (Fuller et al., 2002). Individuals with prodromal schizophrenia symptoms 
often present deficits, ranging in intensity from almost normal conditions to the ones, 
resembling mental status of patients with the first episode of their disease (Lencz et al., 
2006). In this aspect, neurocognitive disorders can be considered as the initial schizophrenia 
symptoms (Javitt, 2010). Due to these reasons, the cognitive disorders appear to be closely 
connected with the etiology of schizophrenia (Kantrowitz & Javitt, 2010b). 
In schizophrenia, the cognitive dysfunctions and hypofrontality are associated with 
hypofunction of NMDA receptors (NMDA-R) (Marek et al., 2010), and according to 
Carlsson (2006), an abnormal function of NMDA-R is the main cause of schizophrenia. 
These cognitive disorders, mostly in form of concentration deterioration, and deficits of 
operative memory are results of prefrontal cortex dysfunctions, which are related to the 
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deficit of glutamergic transmission, caused by the NMDA-R hypofunction (Thomsen et al., 
2009). 
There are two pharmacological models of the NMDA-R (receptor) hypofunction – acute and 
chronic (Pratt et al., 2008). Acute receptor antagonist model relates to a short-term 
administration of the NMDA-R antagonist. In this situation, blocking the NMDA-R causes 
disinhibition of neurotransmission and so called hyperfrontality that means increased 
glutamergic activity in the areas of prefrontal cortex (Homayoun & Moghaddam, 2007). 
There is indirect evidence that some cerebral metabolic disorders, in the acute phase of 
schizophrenia, resemble the changes that were observed experimentally, during 
administration of the NMDA-R antagonists, directly to different areas of the brain 
(Bubeníková-Valesová et al., 2008). Also, a significant increase of the glutaminic acid 
concentration in the cingular area has been noted both in patients with an early psychosis 
(Théberge et al., 2002), and with prodromal schizophrenia symptoms (Stone et al., 2009).  
Pratt et al. (2008) proposed a chronic psylocybine (PCP) model, which explains a relation 
between the NMDA receptors hypofunction and hypofrontality. Chronic administration of 
the PCP to rats caused a reduction of glucose metabolism in their prefrontal cortex, and a 
decrease in the expression of protein marker of gamma aminobutyric acid (GABA) 
interneuron’s’ activity. In schizophrenia patients, similarly to chronic PCP abusers, the 
hypofrontality symptoms and GABA interneuron’s deficits have been noted. According to 
the Pratt’s model, hypofrontality represents neuroadaptation, created during a period of 
long-term glutamergic hyperfunction, caused by a chronic blockage of the NMDA-R, related 
to GABA interneurons.  
Based on some studies, the cognitive deficits appear a few years prior to the onset of 
schizophrenia (Fuller et al., 2002; Kantrowitz et Javitt, 2010b), but there is no convincing 
evidence that they are present since early childhood (Paz et al., 2008; Perkins et al., 2005). A 
28-year observational study by Seidman et al. (2006) has revealed that the patients with 
schizophrenia displayed some minor concentration disorders already at the age of 7 years. 
These disorders are subsequently aggravated, with the development of the disease. 
However, the exact moment of aggravation is still unknown. It is possible that the disorders’ 
exacerbation can occur just before the first schizophrenia episode.  
2. Study design 
Our unpublished study results indicate the persistence of cognitive dysfunctions in 
schizophrenia, and are convergent with some recent research data in this area. 
In our study, cognitive functioning was assessed with neuropsychological tests, included in 
the Vienna System Tests. Functions of attention, operational memory, learning and motor 
reactions were also examined. A battery of Cognition (COG), Block Taping Test (CORSI), 
SIGNAL and Reaction Test (RT) tests was performed in all of our paranoid schizophrenia 
patients. 
3. Study group 
We studied a group of 162 paranoid schizophrenics, treated with 3 different neuroleptics, or 
treatment-resistant patients (Figure 1).  
Patients who were recruited to this study were diagnosed with paranoid schizophrenia, and 
treated in monotherapy with one of the following neuroleptics: haloperidol, clozapine or 
www.intechopen.com
 
Neurocognitive Expression of Hypofrontality in Long Term Schizophrenia 
 
95 
olanzapine. Subjects in the study group met the contemporary criteria of symptomatic 
remission in schizophrenia. The study covered also a group of chronically ill schizophrenic 
subjects, who were resistant to the pharmacologic treatment, and did not have the 
remission. 
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28%
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resistant group
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Fig. 1. Percentages of paranoid schizophrenia patient’s sub-groups, treated with haloperidol, 
clozapine, olanzapine, and treatment-resistant. Results are shown as percentages (%) of the 
entire study group. 
The gender characteristics of the study patients are shown in Figure 2.  
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Fig. 2. Gender of patients in the study groups. Results are expressed as percentages (%) of 
the entire study group. 
The mean age of patients was 46.1 years. The age of patients in the study groups is shown in 
Figure 3. 
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Fig. 3. Age of patients in the study groups. Results are expressed as the mean ± standard 
deviation (SD). 
An average disease onset was at the age of 27.4 years (mean age) (Figure 4), and the mean 
period of the disease duration was 19.3 years (Figure 5).  
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Fig. 4. The age of schizophrenia onset in the study groups of patients. The results are shown 
as means ± standard deviation (SD). 
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Fig. 5. The duration of the disease in the study groups of patients. The results are shown as 
means ± standard deviation (SD). 
The mean numbers of hospitalizations of the study patients are shown in Figure 6. 
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Fig. 6. The number of hospitalizations in the study groups of patients. The results are shown 
as means ± standard deviation (SD). 
The results were analyzed statistically using non-parametric Kruskal-Wallis test and Tukey 
HSD test for unequal sample sizes. NIR post-hoc test was also applied. Confidence interval 
(CI) was established at the level of 95%. The results were established as statistically 
significant at p<0,05. 
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4. Results 
The intensity of negative symptoms was significantly below, as compared to the results of 
patients treated with neuroleptics. It was shown both in the global results of Negative 
Symptom Assessment Scale (NSA-16) (Figure 7) and in its sub-scales assessing alogy 
(Figure 8), blunted affect (Figure 9), asociality-anhedonia (Figure 10) and avolition-apathy 
(Figure 11). 
The intensity of negative symptoms, measured with NSA-16 was 32% lower in the group 
of patients treated with neuroleptics, as compared with the treatment resistant subjects 
(Figure 7). 
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Fig. 7. Results of NSA-16 scale, in paranoid schizophrenia study groups of patients. Results 
are shown as means with standard deviation (SD). H3,162=84,7, p=0,00001, η2P=0,53.  
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Fig. 8. Results of NSA-16 alogy subscale, in paranoid schizophrenia study groups of 
patients. Results are shown as means with standard deviation (SD). H3,162=70,7, p=0,00001, 
η2P=0,43. 
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Fig. 9. Results of NSA-16 blunted affect subscale, in paranoid schizophrenia study groups of 
patients. Results are shown as the means with standard deviation (SD). H3,162=65,6, 
p=0,00001, η2P=0,49. 
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Fig. 10. Results of NSA-16 asociality-anhedonia subscale in paranoid schizophrenia study 
groups of patients. Results are shown as the means with standard deviation (SD). 
H3,162=60,3, p=0,00001, η2P=0,35. 
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Fig. 11. Results of NSA-16 avolition-apathy subscale in paranoid schizophrenia study 
groups of patients. Results are shown as the means with standard deviation (SD). 
H3,162=77,5, p=0,00001, η2P=0,46. 
In the alogy subscale of NSA-16, the intensity of symptoms was 39,7% lower in the group of 
treatment resistant schizophrenic patients (Figure 8).  
In the blunted affect subscale of NSA-16, the intensity of symptoms was 26,1% lower in the 
patients treated with neuroleptics (Figure 9).  
The intensity of symptoms, according to asociality-anhedonia subscale of NSA-16, was 35,3 
% higher in the treatment resistant schizophrenic patients group (Figure 10). 
An analysis of the avolition-apathy subscale of NSA-16 revealed that the intensity of 
symptoms was 34,7% higher in the treatment resistant schizophrenia patients (Figure 11). 
A clinical state of the study patients was assessed with the Clinical Global Impression–
Severity (CGI-S) scale. Comparison of global clinical picture between the patients without 
remission and the patients effectively treated with neuroleptics revealed the significant 
difference (Figure 12).   
In patients with remission, the intensity of the disease was assessed as minimal, but in the 
group of patients with residual symptoms, the intensity measured with CGI-S was moderate 
to severe.  
An analysis of Person’s correlation coefficient has revealed that in the group of patients 
without remission, the severity of the symptoms correlated with the intensity of negative 
symptoms, measured with NSA-16 scale (R=0,65, p=0.0001). The intensity of both positive 
(R=0,58, p=0.0001) and negative (R=0,37, p=0.0001) symptoms, in the study groups of 
patients was assessed, according to Positive and Negative Syndrome Scale (PANSS).  
In patients treated with haloperidol, the severity of the disease correlated significantly 
(R=0,33, p=0,03) with the intensity of extrapyramidal symptoms, assessed with Simpson-
Angus Extrapyramidal Symptoms Scale.      
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Fig. 12. Assessment of clinical state of paranoid schizophrenia, in study groups of patients, 
with Clinical Global Impression–Severity (CGI-S) scale. Results are shown as means with 
standard deviation (SD). H3,162=117,3, p=0,0001, η2P=0,82. 
Cognitive dysfunctions of various intensity were present in all groups of the study patients. 
They included disturbances of: attention, operational memory, learning mechanisms, and 
reaction time. These dysfunctions were present, even though the patients met the criteria of 
functional remission, and were treated with neuroleptics.  
An analysis of logistic regression has indicated that the cognitive deficits in subjects with 
schizophrenia depended on the intensity of negative symptoms and are related to the 
schizophrenic process. However, these symptoms did not depend on the duration of the 
disease, and on the age of schizophrenia onset. 
5. Discussion 
Many authors indicate the steady persistence of cognitive dysfunctions, during the entire 
schizophrenia course.  
In the study by Klingberg et al. (2008), alterations of cognitive functioning among 
schizophrenia patients were noted over the period of 15 months. Despite improvement of 
memory and concentration, comparing to the beginning of the disease, after a successful 
treatment of the acute episode, the patient’s cognitive functioning, during the entire 
observation period did not return to normal level.  
Also, in their 5-year study, Albus et al. (2006) indicated that the cognitive dysfunctions in 
schizophrenia were present from the beginning of the disease, and then, they remained 
stable, over the consecutive years. Both classical and atypical neuroleptics did not have any 
significant influence on these cognitive deficits, except from verbal fluency.  
Likewise, the study by Kurtz et al. (2005), conducted on a small group of patients, indicated 
the presence of persistent deficits of cognitive functioning in schizophrenia, during the 
observation period of 10 years.  
Another 10-year observation conducted by Stirling et al. (2003) has revealed that the 
deterioration of cognitive functioning in schizophrenia remained at a similar level during 
the entire duration of the disease. According to the same author, the deficit of executive 
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functions was present already at the onset of the disease, and did not increase over the next 
10-12 years.  
According to a 10-year observation by Hoff et al. (2005), it was fund that the cognitive 
deficits had arisen prior to the first hospitalization, and subsequently lasted, without any 
significant deterioration, over the entire disease period. 
Based on the study by Øie et al. (2010), the cognitive disorders among schizophrenic 
patients, especially in the spectrum of verbal memory, attention, and information processing 
speed, remained almost unchanged, despite a 13-year period of treatment. These cognitive 
deficits were present, despite the improvement of clinical symptoms, over a few years, after 
the first schizophrenia episode (de Mello Ayres et al., 2010).  
The above research findings indicate that the cognitive disorders among patients with 
schizophrenia appear at the beginning of the disease, or even before the stage of full-blown 
disease, and then, they can be stable chronically. 
According to contemporary standards of schizophrenia treatment, neuroleptics play the 
main role in therapy. Treatment starts at the beginning of acute schizophrenia episode, 
when a patient meets diagnostic criteria of the disease, including fully expressed positive 
schizophrenia symptoms. A hypothesis of the NMDA receptors’ hypofunction and the 
associated cognitive disorders in schizophrenia indicate that the moment of treatment 
initiation is delayed by a few years. 
Contemporary knowledge about cognitive disorders in schizophrenia reveals that they arise 
approximately 3-4 years before the first schizophrenia episode, and then, they last over the 
entire lifespan, at a stable level. Our study findings have confirmed the above results. The 
intensity of cognitive disorders among our study patients was not related to the duration of 
the disease. Despite an effective treatment, in patients suffering from this disease for many 
years, the attention disorders, operative memory deficits, as well as learning and reaction 
speed abnormalities persisted.  
It seems that the primary cause of schizophrenia is closely related to the hypofunction of 
NMDA receptors. Pathogenetic process, dependent on the hypofunction of these receptors is 
initiated by disinhibition of neurotransmission in the OUN and hyperfrontality. Long-term 
effects of the glutamergic hypofunction in the OUN lead to hypofrontality, through 
mechanisms of neuroadaptation. Chronic persistence of cognitive dysfunctions, despite the 
effective symptomatic treatment indicates that the currently used neuroleptics do not 
normalize functions of glutamergic system.  
This lack of normalization of the glutamergic system activity with the neuroleptics, explains 
their unsatisfactory therapeutic effect on the cognitive dysfunctions in schizophrenia. 
Treatment of these symptoms represents a very important pharmacotherapy goal in 
psychiatry, because the patients’ quality of life depends mostly on the level of cognitive 
deficits, and intensity of negative symptoms.  
According to a model of hypofunction of the NMDA receptors in schizophrenia, the 
treatment should already be started at the stage, in which the first cognitive disorders 
appear. Since the primary cause of glutamergic malfunction in schizophrenia is the 
hypofunction of NMDA receptors, related to GABA-ergic interneurons, the initial stage of 
therapy should include their stimulation, which can cause the return of inhibition of this 
neurotransmission in OUN. One of the considered medications in this area is acamprosate – 
a GABA-ergic agent, which normalizes the NMDA receptor functions and the release of 
glutamate (De Witte et al., 2005). In the second stage of the disease, characterized by 
hypofrontality and cognitive dysfunctions, the treatment should be focused on increasing 
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the activity of glutamergic system. In the meantime, as indicated by our study results, the 
neuroleptics, through altering composition of different subunits of the NMDA receptor, can 
reduce its activity.  
It appears that the treatment strategy, which considers the model of NMDA receptor 
hypofunction, can create a new direction of research in psychiatry.  
Some proglutamergic agents, which are now under clinical investigation, may become a 
new generation of anti-schizophrenic drugs, in the future. They may also, like D-cycloserine 
- act as agonists of the NMDA receptor, or like sarcosice - inhibit the reverse uptake of 
glycine (Krzystanek et al., 2009). 
6. Conclusion 
The presented results strongly support an argument that schizophrenia may not be related 
to a degenerative process. The cognitive dysfunctions, as the first line of schizophrenic 
symptoms, can remain in schizophrenic patients for their lifetime, despite achieving clinical 
remission. 
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